407
Participants
Start Date
May 17, 2022
Primary Completion Date
May 30, 2025
Study Completion Date
September 30, 2027
IO102-IO103
IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
Pembrolizumab
Pembrolizumab administered intravenously
IRCCS Istituti Fisioterapici Ospitalieri, Roma
Adana City Education and Research Hospital, Adana
The Netherlands Cancer Institute, Amsterdam
AMC Amsterdam, locatie VUMC, Amsterdam
Orszagos Onkologiai Intezet, Budapest
Westmead Hospital, Westmead
Southern Medical Day Care Centre, Wollongong
Border Medical Oncology Research Unit, Albury
Herlev og Gentofte Hospital, Herlev
Peter MacCallum Cancer Centre PMCC - East Melbourne, Melbourne
University Medical Center Utrecht, Utrecht
Sunshine Coast University Hospital, Birtinya
Cairns Hospital, Cairns
Odense University Hospital, Odense
Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok
The Queen Elizabeth Hospital, Woodville South
Flinders Medical Centre, Bedford Park
Gulhane School of Medicine, Ankara
Universitatsklinik fur Dermatologie und Venerologie der MLU Halle-Wittenberg, Halle
Ospedale S. Maria della Misericordia, Perugia
CHU de Nice Hpital de lArchet 2, Nice
Memorial Ankara Hospital, Ankara
Akdeniz University Medical Faculty, Antalya
Cape Town Oncology Trials (Pty) Ltd., Cape Town
Bor, -Nemikortani es Onkodermatologiai Klinika, Pécs
Instituto Oncologico Dr. Rosell IOR - Hospital Universitari Quiron Dexeus, Barcelona
Aarhus University Hospital, Aarhus
Hospital Universitari Germans Trias i Pujol HUGTP, ICO-Badalona, Barcelona
Universitair Ziekenhuis Gent UZ Gent, Ghent
Aalborg University Hospital, Aalborg
AZ Nikolaas, Sint-Niklaas
FNKV Department of Dermatology, Prague
IRCCS Ospedale San Raffaele, Candiolo
Charite Universitaetsmedizin Berlin, Berlin
Hôpital de La Timone, Marseille
Roswell Park Cancer Institute, Buffalo
CH Universitario de A Coruña (CHUAC), A Coruña
IRCCS Ospedale Policlinico San Martino, Genova
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Centre Georges Francois Leclerc, Dijon
Elbe Klinikum Buxtehude, Hamburg
VCU Massey Cancer Center, Richmond
Universitaetsklinikum Schleswig-Holstein, Kiel
Centre Hospitalier Universitaire de Besançon Jean Minjoz, Besançon
Hospital General Universitario Gregorio Marañon, Madrid
Clinica Universidad de Navarra, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Hospital Regional Universitario de Malaga, Málaga
Clinica Universidad de Navarra, Pamplona
Mühlenkreiskliniken AöR, University Hospital Ruhr University Bochum Campus Minden, Minden
Mid Florida Hematology and Oncology Center, Orange City
Orlando Health Cancer Institute, Orlando
Hospital Universitario Central de Asturias (HUCA), Oviedo
Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre, Bordeaux
Centro di Riferimento Oncologico, Aviano
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul
Centre Eugene Marquis, Rennes
Ege university Faculty of Medicine, T. Aktas Oncology Hospital, Bornova, Bornova
Veneto Oncology Institute, Padua
Chu Grenoble - Hopital Albert Michallon, La Tronche
Hospital Universitario Virgen Macarena, Seville
St. Josef Hospital - Ruhr-Universitt Bochum, Bochum
Institut de Cancérologie de L'Ouest, Saint-Herblain
Universitaetsklinikum Essen, Essen
Hospital General Universitario de Valencia, Valencia
Hospital Universitari i Politecnic La Fe, Valencia
"Istituto Romagnolo per lo Studio dei Tumori DINO AMADORI", Meldola
Universitaetsklinikum Muenster, Münster
Miguel Servet University Hospital, Zaragoza
Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte, Siena
Department of Dermatology University of Mainz, Mainz
Centre Hospitalier Universitaire de Lille, Lille
Clinica Oncologica, AOU Riuniti ancona, Ancona
University Hospital Frankfurt Theodor-Stern-Kai, Frankfurt
Universitatsmedizin Mannheim Dermatologie, Mannheim
Nationales Centrum fr Tumorerkrankungen NCT, Heidelberg
Centre Hospitalier Lyon Sud, Pierre-Bénite
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari
Hospital Tubingen, Tübingen
SLK-Kliniken Heilbronn GmbH, Heilbronn
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli
LMU Muenchen, München
Ben-Gurion University of the Negev - Soroka University Medical Center - Soroka Clinical Research Center, Beersheba
Universitatsklinikum Augsburg Medizincampus Sued, Augsburg
University Hospital Erlangen, Erlangen
Hadassah University Hospital, Jerusalem
Hopital Ambroise, Boulogne-Billancourt
Gustave Roussy, Villejuif
Universittsklinikum Wuerzburg, Würzburg
Rabin Medical Center, Petah Tikva
The Chaim Sheba Medical Center - The Ella Lemelbaum Institute for Immuno-Oncology, Tel Litwinsky
FNHK Klinika onkologie a radioterapie, Hradec Králové
Fakultni Nemocnice Olomouc, Olomouc
FN Ostrava, Ostrava
Centre Hospitalier de Valence (CHV), Valence
Emek Medical Center, Afula
Tel Aviv Sourasky Medical Center, Tel Aviv
Hospital Vall d'hebron, Barcelona
Idi-Irccs, Rome
LUMC, Leiden
UMC Maastricht, Maastricht
Erasmus MC, Rotterdam
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan
Mary Potter Oncology Centre Groenkloof, Pretoria
Hospital Clinic i Provincial, Barcelona
Guy's Hospital, London
Christie Hospital NHS Trust, Manchester
Christie Hospital NHS Trust, Manchester
Oxford University Hospitals NHS Foundation Trust, Oxford
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
IO Biotech
INDUSTRY